anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: The use of circulating tumor DNA (ctDNA) assays to guide clinical decision-making in early-stage colon cancer is an area of rapidly advancing active research. With assays clinically available, clinicians must be informed how to best use this novel tool to treat patients.
RECENT FINDINGS: Recent observational and prospective studies have suggested that ctDNA has potential to guide clinical decision-making in early-stage colon cancer by detecting minimal residual disease (MRD) and predicting recurrence risks. MRD-negative patients may be able to de-escalate or forgo adjuvant chemotherapy (ACT) without compromising disease-free survival or overall survival, while MRD-positive patients may benefit significantly from ACT. Recent and ongoing studies have given reason for optimism about the future of ctDNA as a useful biomarker for clinicians treating early-stage colon cancer. Data thus far are mostly limited to observational studies; inconsistent results highlight the need for caution. As more evidence emerges, ctDNA may become standard of care for colon cancer patients.
AndroGel 1.62% for topical use is a clear, colorless gel containing testosterone. Testosterone is an androgen. AndroGel 1.62% is available in a metered-dose pump or unit dose packets. 

The active pharmacologic ingredient in AndroGel 1.62% is testosterone. Testosterone USP is a white to almost white powder chemically described as 17-beta hydroxyandrost-4-en-3-one. The structural formula is: 

The inactive ingredients in AndroGel 1.62% are: carbopol 980, ethyl alcohol, isopropyl myristate, purified water, and sodium hydroxide.
Cadmium-contaminated water and food are seriously hazardous to the human health, especially liver injury. To understand the entanglement relationship between cadmium ion (Cd2+)-induced liver injury and the biomarker sulfur dioxide (SO2), a reliable bioanalytical tool is urgently needed, detecting SO2 to diagnose and evaluate the extent of liver injury in vivo. Herein, based on the Förster resonance energy transfer (FRET) mechanism, a novel SO2-tunable NIR ratiometric fluorescent probe (SMP) was developed, it was used to diagnose and treat liver injury induced by Cd2+ in biosystems. Specifically, it was constructed by conjugating a NIR dicyanoisophorone with a NIR benzopyranate as the donor and acceptor, respectively, and the ratiometric response of SO2- regulated by the Michael addition reaction. In addition, SMP exhibits rapid reaction time (<15 s), two well-resolved emission peaks (68 nm) with less cross-talk between channels for high imaging resolution, superior selectivity, and low limit of detection (LOD=80.3 nM) for SO2 detection. Impressively, SMP has been successfully used for intracellular ratiometric imaging of Cd2+-induced SO2 and diagnostic and therapeutic evaluation in liver injury mice models with satisfactory results. Therefore, SMP may provide a powerful molecular tool for revealing the occurrence and development relationship between SO2 and Cd2+-induced liver injury. ENVIRONMENTAL IMPLICATION: Cadmium ions are one of the well-known toxic environmental pollutants, which are enriched in the human body through inhalation of cadmium-contaminated air or from the food chain, leading to damage in various organs, especially liver injury. Therefore, we developed a novel fluorescent probe that can specifically detect SO2 in Cd2+-induced liver injury, which is critically important for the diagnosis and evaluation of Cd2+-induced liver injury diseases. The specific detection of SO2 of this probe has been successfully demonstrated in live HepG2 cells and Cd2+-induced liver injury mice.
Medicine in Germany is currently facing major structural and economic challenges. Infectious Diseases, with the recent introduction of a new specialty in "Internal Medicine and Infectious Diseases" and with the existing additional training for almost all specializations, will make an important contribution to overcoming these challenges. Expertise in infectious diseases has to be very broad and requires high interdisciplinarity, which makes infectious diseases an attractive and demanding specialty. The complex fundamentals of infectious diseases must now be quickly conveyed to as many physicians as possible in a short period of time, as part of their specialization or as additional training. Until this is achieved, transitional solutions will be necessary for some time. The adaptation of the current billing and reimbursement system for infectious diseases services and improved intersectoral cooperation are of the utmost importance for the further development of the specialty.
The method of rehabilitation of non-psychotic mental disorders in the patients with pancreatitis comprises the sanitary and health improvement measures as well as the dietary and therapeutic and diagnostic measures. Therapeutic and diagnostic measures are provided sequentially in four stages. The first stage for 1-2 days provides for diagnosis based on psychometric scales, the phytotherapy sessions begin with taking a mixture of tinctures of valerian, hawthorn and motherwort thrice a day. At the second stage, the baseline pharmacotherapy starts with by taking antidepressant at the doses chosen on an individual basis. The antidepressant is selected individually from the selective serotonin reuptake inhibitors, serotonergic and melatoninergic substances. The third stage consists in the control assessment of the state of the patient using psychometric scales. Then the dose of the selected antidepressant is corrected. Finally, the antidepressant for prophylaxis is selected taking into account for long-term tolerability.
In each patient, each one of the two scars, or each side of a large scar will be assigned to one of the following treatment methods: 1-Fractional microneedling radiofrequency 2-Intralesional steroids injection. Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz. For intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. All patients will receive 5 treatment sessions 4 weeks apart.
It is currently established that obtaining a large number of oocytes is a key of success in IVF/ICSI cycles. However, it is also a risk factor for ovarian hyperstimulation syndrome (OHSS) and a risk factor of implantation failure after fresh embryo transfer because of the alteration of endometrial receptivity. A freeze all strategy can be proposed to avoid these risks but vitrification of embryos, although more efficient than slow freezing in terms of embryo survival, is not without risk. Furthermore, proper endometrial and embryo timing for frozen-thawed embryo transfer is still debated.

Recent preliminary works suggest another possible way to combine an optimal ovarian response with the recovery of a large number of oocytes, good chances of implantation and a reduced risk of OHSS. To achieve this goal, ovulation triggering and luteal phase support need to be modified together. The human chorionic gonadotropin (hCG) (mimicking the Luteinising Hormone (LH)peak to trigger ovulation) that induces OHSS is replaced by an a GnRH agonist (GnRHa) triggering allowing an endogenous peak of Follicle Stimulating Hormone (FSH) and LH. Then, the usual support of the luteal phase by exogenous vaginal progesterone, whose absorption seems to be suboptimal for about 30% of patients, is replaced by endogenous progesterone production by the corpora lutea, supported by the maintenance of LH activity through the continuation of agonist of gonadotropin releasing hormone (AgoGnRH) in the luteal phase. Pilot studies show that a 10% to 15% increase in ongoing pregnancy rates can be expected with this type of protocol. The objective of our study is to demonstrate an increase in ongoing pregnancy rate per cycle with this new strategy combining GnRHa triggering and GnRHa luteal phase support compared to the reference protocol (hCG triggering and exogenous progesterone luteal phase support).
Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca 2+ -channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca 2+ -channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca 2+ -channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca 2+ -channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier. Additionally, pharmaceutical compositions having a Ca 2+ -channel blocker, a hypertensive agent, and a pharmaceutically-acceptable carrier are provided.
The invention relates to the preparation and use of .alpha.,.beta.-unsaturated aldehydes in the structure of sulphated polysaccharides. These are derivatives with the conjugated double bond in position 4 and 5 of the galactopyranose part located towards the aldehyde group in position 6 according to general structural formula I or a hydrated form according to general structural formula II. The method of preparation of these derivatives is based on sulphated polysaccharides containing the galactopyranose cycle sulphated in position 4, which is bound in the polymeric chain by the .alpha. (1→3) or .beta. (1→3) O-glycosidic bond. In the solution described, sulphated polysaccharides are subject to regio- and chemoselective oxidation while forming a saturated C-6 aldehyde which, by the direct elimination of the sulphate group, provides an .alpha.,.beta.-unsaturated derivative of general formula I or II. The solution described is technologically advantageous because it leads directly to the .alpha.,.beta.-unsaturated aldehydes, without requiring elimination reagents, increased temperature, or isolating the intermediate product of the synthesis. The conjugation in the structure of the .alpha.,.beta.-unsaturated aldehyde enables, under physiological conditions, binding a wider variety of biocompatible amines in the structure of sulphated polysaccharides. The proposed procedure allows preparation of materials suitable for pH-responsive carrier systems, or for the preparation of scaffolds in tissue engineering and regenerative medicine.
Systems and methods for detennining and filling unfulfilled appointments with stand-by patients. The unfulfilled appointment can be due to a no-show or inadequate preparation. The system can predict the unfulfilled appointment for a provider based on geography, patient calendar schedules, and other variables. In an example, the unfilled appointment is filled by a patient based on calendar availability and within a geographical proximity at the time of the unfulfilled appointment. The system can detennine the unfulfilled appointment prior to a scheduled appointment, the length of time allotted to the scheduled appointment, prioritizing the eligible patients, alerting the eligible patients, receiving patient acceptance to fill the unfulfilled appointment, and selecting one of the patients to fill the unfulfilled appointment. The selected patient now has a sooner appointment than their originally scheduled appointment. The provider has now filled the potentially unfulfilled appointment by replacing with a new patient, saving resources.
NEW MATERIAL:The urokinase derivative having the group of formulaI(R is H, alkyl or alkanoyl; n is 0-500; A is active group which can bond with amino group) bonded to the lysine residue and the N-terminated amino group of urokinase. EXAMPLE:Monomethyl ether polyethylene glycol-4,6-dichloro-1,3,5-triazine-modified urokinase. USE:Thrombolytic agent. It is physically stable and keeps its fibrinolytic activity for an elongated time interval when administered in the body. PROCESS:The urokinase derivative having the group of formulaIbonded thereto can be prepared by reacting a polyethylene glycol derivative of formula II (X is halogen or azido) with urokinase at 7-9 pH in an aqueous solution such as buffer solution at a low temperature to suppress the activity lowering. The derivative is useful for the remedy of diseases such as arterial and venous thrombosis, coronary occlusion, myocardial infarction, intracerebral infarction, etc.
On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
The present invention discloses a pharmaceutical kit consisting of composition I and composition II. Composition I comprises a viable Measles virus (MeV), Edmonston Zagreb vaccine strain with one or more pharmaceutical excipients. Composition II comprises a viable, Vesicular stomatitis virus (VSV) Indiana strain according to ATCC, with one or more pharmaceutical excipients. The final dosage forms are a suspension or a lyophilized powder for reconstitution of injectable suspension. The compositions I and II from the said kit are administered by a specific dosage regimen as a therapy complementing surgical excision. The dosage regimen in combination with surgery enables effective therapeutical treatment of carcinomas, in particularly the treatment of early-stage breast cancers, including locally recurrent breast cancer.
BACKGROUND: Epiretinal membrane (ERM) causes visual impairment such as reduction in visual acuity and metamorphopsia due to retinal traction. With the improvement of optical coherence tomography (OCT) and microincision vitrectomy surgery (MIVS), the surgery of ERM has significantly advanced. However, there have been no large-scale studies on the following: (1) how to evaluate visual impairment in ERM, (2) the relationship between OCT findings and visual function, (3) when is the optimal timing of surgery, and (4) the relationship between the surgical instruments as well as techniques and prognosis. The purpose of this study was to obtain evidence regarding these ERM surgeries.
METHODS AND DESIGN: This is a prospective, multicenter cohort study of ERM surgery in Japan from March 1, 2023, to March 31, 2027 (UMIN000048472, R-3468-2). Patients who underwent ERM surgery during the study period and agreed to participate in this study will be included. The goal is to have a total of 5,000 eyes surgically treated for ERM. The following data will be collected: age, gender, medical history, subjective symptoms, visual function before and 6 and 12 months after surgery, clinical findings, OCT data, surgical technique, instruments used in surgery, and complications.
DISCUSSION: The results of this study will support the surgical decisions and procedures in ERM practices.
Participants will be enrolled in a 3 month, 5 session in-person diabetes nutrition education class, entitled What Can I Eat?, over the course of the 3 month intervention (4 \* 90 min in person classes weekly for a month, with 5th class at 3 months from baseline). Additionally, patients will receive a $30.00 healthy food resource weekly for 12 weeks.
Individuals with MS in the second group will be given balance exercises with stroboscopic glasses for 15 minutes. Exercises will be selected in accordance with the functional level of the individual and will progress according to the individual's condition. In each session, 3-5 different exercises will be performed, taking into account the functional status of the individual.
Ramipril and ramiprilat inhibit ACE in human subjects and animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with ramipril alone for up to 56 weeks, approximately 4% of patients during the trial had an abnormally high serum potassium and an increase from baseline greater than 0.75 mEq/L, and none of the patients had an abnormally low potassium and a decrease from baseline greater than 0.75 mEq/L. In the same study, approximately 2% of patients treated with ramipril and hydrochlorothiazide for up to 56 weeks had abnormally high potassium values and an increase from baseline of 0.75 mEq/L or greater; and approximately 2% had abnormally low values and decreases from baseline of 0.75 mEq/L or greater [see Warnings and Precautions ( 5.8)] . Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. 

The effect of ramipril on hypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma.

Angiotensin converting enzyme is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasopressor peptide, play a role in the therapeutic effects of ramipril remains to be elucidated.

While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypertension. Although ramipril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a blood pressure lowering response to monotherapy, albeit a smaller average response, than non-Black patients.
Mild traumatic brain injury (mTBI) is a common cause of admission to the Emergency Department (ED). Many patients are elderly on oral anticoagulant therapy (OAT) at increased risk of immediate and delayed intracranial hemorrhage (ICH). To investigate the frequency of delayed ICH (DICH) in old patients with mTBI in OAT and the occurrence of complications related to the ED stay. In this single-center retrospective study, we recruited all patients in OAT aged 65 and over, admitted for mTBI to the ED of our Hospital in Florence from March 2019 to February 2021. Clinical variables were collected and cranial computed tomography (CT) scans reviewed. The primary outcome was the frequency of DICH occurring within 30 days since the trauma after a first negative CT. Secondary outcomes included need of neurosurgical intervention and death for DICH, and hospital-related complications. Statistical analyses were conducted using IBM SPSS Statistics (version 22). Among 363 enrolled patients, there were 31 acute ICH (8.5%) at the first CT scan, while in the 316 negative included patients, 10 DICH (3.2%) were identified. Among the latter, no neurosurgical treatment, or death due to ICH occurred. Overall, 25 cases (6.9%) had iatrogenic complications during the 24-h observation period, often serious, such as respiratory failure after sedation due to restlessness, or COVID-19 infection. The low frequency of DICH and the occurrence of several iatrogenic complications suggest that the risk-benefit ratio of a 24-h ED observation is not advantageous in elderly with mTBI.
The invention provides a multi-component homogenous co-crystallized low sodium salt product for food and pharmaceutical use. The salt product of the invention is essentially segregation-free, has low hygroscopicity and is free-flowing. It has good microbial depression properties and good taste. It supplies the functionality of salt (NaCl) in processed foods and it also maintains the microbial safety, nutritional value and taste. The salt product of the invention includes an alkaline and alkaline earth metal chloride component and an ammonium chloride component. An alkaline metal is potassium (K), and optionally also sodium (Na). An alkaline earth metal is Magnesium (Mg) or Magnesium (Mg) and Calcium (Ca) having the sum of the molar ratios 1. The invention provides also a process to produce the salt products of the invention.
FIELD: medicine, surgery. SUBSTANCE: three days before operation one should introduce "Forlax" per one packet thrice daily. One day before the onset of electrotherapy it is necessary to conduct laser irradiation of perianal area for 7-10 min. Before said procedure it is introduced 0.5 ml "Alloplant" dispersed biomaterial into a node. On finishing electrotherapy course one should repeat laser irradiation of perianal area. The present method inhibits the development of scar connective tissue and accelerates the regeneration process. EFFECT: higher efficiency of therapy. 1 tbl
A cleansing pad (10) is made of a web of fibers, forming a substrate (11), where the substrate (11) includes a cleansing agent (12) therein. The cleansing agent (12) is a pourable soap. In making the cleansing pad (10), the cleansing agent (12) is initially heated from solid form into molten/liquid form, and distributed essentially throughout one or more portions of the substrate (11) in molten form to coat the fibers in said portions of the substrate (11). After application of the molten cleansing agent (12), the substrate (11) is then allowed to cool such that the molten cleansing agent (12) solidifies and remains solid at a desired range at and above room temperature, forming the cleansing pad (10). Thereafter, in use, the cleansing pad (10) is applied for cleaning an object in conjunction with a solvent such as water. The solvent dissolves the solidified cleansing agent (12). The cleansing pad (10) can be used in this manner multiple times without the need for application of additional cleansing agent (12) to the cleansing pad (10). As such, the cleansing pad (10) is a self- contained, long lasting product that maintains its creamy lather during multiple uses and does not require the user to reapply cleansing agents to the cleansing pad (10) with every use.
PURPOSE: To prepare the subject foaming aqueous solution by introducing a mixture of anhydrous solid compounds consisting of urea, an alkali metal carbonate and/or ammonium bicarbonate, pyrrolidonecarboxylic acid and a specific water-soluble component into an aqueous medium at a specific ratio. CONSTITUTION: This foaming aqueous solution having softening activity on the cuticule of a nail is prepared by introducing 1-15g of a mixture of anhydrous solid compounds consisting of (A) 10-25 pts.wt. of urea, (B) 50-90 pts.wt. of a mixture of an alkali metal salt and/or ammonium bicarbonate and pyrrolidonecarboxylic acid [weight ratio of bicarbonate salt: PCA is (1:4) to (4:1)] and (C) 0-40 pts.wt. of a water-soluble component selected from a softening compound other than the above-mentioned compound, a compound for treating nails and an auxiliary agent into 100g of an aqueous medium such as water. The aqueous solution does not affect nails and the skin close to the nails, exhibits softening activity on the cuticule and gives further pleasant feeling by its foaming property.